Moderate

Renal artery stenosis / ischaemic nephropathy (renovascular disease)

Renovascular disease · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Narrowing of one or both renal arteries reducing renal perfusion and activating the renin-angiotensin system. Two main causes: atherosclerotic (older patients, diffuse vascular disease, ostial lesions — commonest) and fibromuscular dysplasia (younger women, mid/distal artery 'string of beads'). Causes secondary/resistant hypertension, 'flash' pulmonary oedema, and ischaemic nephropathy (progressive CKD). A characteristic clue is a significant rise in creatinine after starting an ACEi/ARB (loss of efferent arteriolar tone in a perfusion-dependent kidney, especially bilateral disease). Medical therapy is the default; revascularisation is reserved for selected refractory cases.

Red flags

  • Recurrent 'flash' pulmonary oedema with preserved LV function — suggests bilateral critical stenosis, a recognised revascularisation indication
  • Steep creatinine rise (>30%) or AKI after starting ACEi/ARB — critical bilateral stenosis or stenosis to a solitary kidney
  • Rapidly declining eGFR with a still-viable kidney — consider revascularisation
  • Severe resistant hypertension despite >=3 agents including a diuretic
  • Young woman with severe hypertension + abdominal bruit — FMD (angioplasty often curative)

Assessment

Differential diagnosis

  • Essential/other secondary hypertension (primary aldosteronism, phaeochromocytoma, renal parenchymal disease)
  • Hypertensive nephrosclerosis / CKD of other cause
  • Atheroembolic (cholesterol embolism) renal disease (post-procedure, livedo, eosinophilia)
  • Cardiac failure causing cardiorenal syndrome
  • Thrombotic/thromboembolic renal artery occlusion (acute)

Investigations

  • BP (often resistant), U&E/creatinine/eGFR (baseline + after RAS blockade), potassium (hypokalaemia from secondary hyperaldosteronism)
  • Urinalysis (bland sediment), ACR
  • Duplex ultrasound of renal arteries (first-line non-invasive; raised velocities, resistive index, size asymmetry)
  • CT angiography or MR angiography (anatomy; avoid in advanced CKD/contrast concerns)
  • Consider renal asymmetry (>1.5 cm) and the clinical triad; catheter angiography reserved for when intervention is planned (fibromuscular dysplasia angioplasty)
  • Screen for FMD features in young hypertensives (abdominal/flank bruit, family history)

Management

  • Suspect renovascular disease in: resistant/accelerated hypertension, hypertension onset <30 (FMD) or severe hypertension >55 with vascular disease, 'flash' pulmonary oedema, unexplained progressive CKD, significant creatinine rise after ACEi/ARB, or renal size asymmetry
  • Optimise MEDICAL therapy as the default (ASTRAL/CORAL: routine stenting adds no benefit over medical therapy): BP control, cardiovascular risk reduction (statin, antiplatelet), smoking cessation, glycaemic control
  • Use an ACEi or ARB for BP/renoprotection even in renovascular disease, but monitor U&E closely — a creatinine rise up to ~30% is acceptable; a larger rise suggests critical bilateral stenosis (or stenosis to a single functioning kidney) and the drug may need stopping
  • Avoid ACEi/ARB in known bilateral critical stenosis / stenosis in a solitary kidney if it precipitates significant AKI
  • Reserve revascularisation (angioplasty +/- stent for atherosclerotic; angioplasty for FMD) for selected patients: truly refractory hypertension despite maximal therapy, recurrent flash pulmonary oedema, or rapidly deteriorating renal function with viable kidney
  • Treat FMD with angioplasty (often curative of hypertension) where significant and symptomatic
  • Monitor renal function and BP long term; manage CKD complications per CKD pathway

Drugs & doses

ACEi (ramipril 2.5-10 mg PO once daily) OR ARB (losartan 50-100 mg PO once daily) — monitor U&E; tolerate creatinine rise up to ~30%, investigate/stop if larger (?bilateral disease) [verify local dose]
Add calcium-channel blocker (amlodipine 5-10 mg PO once daily) and/or thiazide-like diuretic (indapamide) for BP control [verify local dose]
Atorvastatin 20-80 mg PO once daily (atherosclerotic disease) [verify local dose]
Antiplatelet (aspirin 75 mg PO once daily) for atherosclerotic cardiovascular risk reduction [verify local dose]
Further antihypertensives (beta-blocker, spironolactone) as needed for resistant hypertension [verify local dose]

Disposition

Mostly outpatient: optimise medical therapy and cardiovascular risk, with nephrology/vascular referral for resistant hypertension, declining renal function, flash pulmonary oedema or suspected FMD. Admit for hypertensive emergency, flash pulmonary oedema or significant ACEi/ARB-induced AKI.

Complications & pitfalls

  • Progressive ischaemic nephropathy / ESKD
  • Resistant hypertension and its end-organ damage
  • Flash pulmonary oedema / cardiac decompensation
  • ACEi/ARB-precipitated AKI in bilateral/solitary-kidney disease
  • Procedural risks of revascularisation (atheroembolism, restenosis, access complications)

Exam pearls

  • A disproportionate creatinine rise (>30%) soon after starting an ACEi/ARB is the classic clue to significant (often bilateral) renal artery stenosis — investigate rather than simply blaming the drug.
  • ASTRAL and CORAL showed routine stenting of atherosclerotic renal artery stenosis adds NO benefit over optimal medical therapy — medical management is the default; reserve intervention for refractory hypertension, flash pulmonary oedema or rapidly failing kidneys with a salvageable kidney [verify local/guideline criteria].
  • Fibromuscular dysplasia is the exception: angioplasty is often curative of hypertension in young patients, so think FMD in a young hypertensive woman with an abdominal bruit.
  • ACEi/ARB are still useful (and renoprotective) in most renovascular disease — just monitor renal function and avoid them when bilateral critical disease causes significant AKI.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.